Arcangelo L.
- Country
- Italy
- Department
- Oncology
Research Overview
- Phase II Study of Pirtobrutinib as Frontline Therapy in Elderly Unfit or Frail Patients with Mantle Cell Lymphoma
- Phase 3 Multicenter Randomized Open-Label Study of Venetoclax and Dexamethasone Versus Pomalidomide and Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma
- Efficacy and Safety Comparison of Obinutuzumab-Venetoclax vs. Obinutuzumab-Chlorambucil in Untreated CLL with Comorbidities
Data & Insights
Has run more than one trial at 177 of 351 partner sites.
Specializations
Hematologic Malignancies
This investigator specializes in treating various blood cancers, with particular emphasis on multiple myeloma and lymphoproliferative disorders.
- Multiple Myeloma Management
- Chronic Lymphocytic Leukemia
- Diffuse Large B-cell Lymphoma
- Follicular Lymphoma
Their research encompasses both newly diagnosed cases and relapsed/refractory disease states.
Therapeutic Approaches
The investigator focuses on innovative treatment combinations involving targeted therapies and immunotherapeutic agents.
- Novel Agent Combinations
- Maintenance Therapy Strategies
- Chemoimmunotherapy Protocols
- Stem Cell Transplantation
Their work includes evaluation of treatment strategies for both transplant-eligible and ineligible patients.
Clinical Focus Areas
The investigator's expertise extends to personalized treatment approaches for various hematologic conditions.
- Early-Stage Disease Management
- Advanced Disease Treatments
- High-Risk Patient Populations
- Treatment Response Assessment
Their research emphasizes improving progression-free survival outcomes across different patient populations.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.